BioSpace News Archive

Clinigen Group plc, the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes in non -small cell lung cancer.” Ben C. Creelan MD, MS from the Thoracic Oncology, Immunology Program of the Moffitt Cancer and Research Institute presented at the American Association for Cancer Research virtual annual meeting on April 28, 2020.

Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be a panelist at the upcoming “Infectious Disease Virtual Conference” presented by Maxim Group. Dr. Balboni will be discussing Appili’s ATI-2307 program, a novel antifungal for resistant infections that the Company acquired from FUJIFI

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced the appointments of Jeffrey A. Chodakewitz, M.D., and Gary Ginsberg to its Board of Directors.

Fully automated immunoassay kit designed to simplify and streamline busulfan therapeutic drug monitoring (TDM), potentially reducing turnaround time from hours to minutes and greatly expanding hospital, clinic, medical office and laboratory access to TDM

CEL-SCI Corporation announced that it has been notified that it has reached the targeted threshold of 298 events required to conduct the data evaluation for its pivotal Phase 3 head and neck cancer study of Multikine* immunotherapy.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced the appointment of Jack Holmes to its Board of Directors.

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GTX-102 for the treatment of Angelman syndrome (AS). GTX-102 is an investigational antisense oligonucleotide cur

Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The planned conversion to these new kits is part of the Company’s ongoing strategy to enhance its global supply chain integrity that was initiated several years ago. “The FDA approval for the new INTERCEPT plasma kit is significant as it is a prerequisite for our p

Neil A. Martin, MD, has joined Pacific Neuroscience Institute (PNI) and Providence Saint John’s Health Center. He also will begin a new role June 1 as regional medical director of neuroscience for Providence Southern California and will help oversee and direct neuroscience activities of the 13 Providence hospitals across Los Angeles and Orange counties and in the High Desert.

Aspargo Laboratories, Inc. (Aspargo), a privately held, clinical stage pharmaceutical company, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed Aspargo’s questions and provided guidance on the Company’s Sildenafil Oral Sp